{"id":"NCT04445519","sponsor":"Nicox Ophthalmics, Inc.","briefTitle":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","officialTitle":"Phase 3, Randomized, Adaptive Dose-Selection, Multi-regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-01","primaryCompletion":"2022-09-16","completion":"2022-09-16","firstPosted":"2020-06-24","resultsPosted":"2025-05-30","lastUpdate":"2025-06-24"},"enrollment":691,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"NCX 470 0.065% (initial phase of trial)","otherNames":[]},{"type":"DRUG","name":"Latanoprost 0.005% (initial phase of trial)","otherNames":["Latanoprost"]},{"type":"DRUG","name":"NCX 470 0.1% (initial phase of trial)","otherNames":[]},{"type":"DRUG","name":"NCX 470 0.1% (remainder of trial)","otherNames":[]},{"type":"DRUG","name":"Latanoprost 0.005% (remainder of trial)","otherNames":[]}],"arms":[{"label":"NCX 470 0.065%","type":"EXPERIMENTAL"},{"label":"NCX 470 0.1%","type":"EXPERIMENTAL"},{"label":"Latanoprost 0.005%","type":"ACTIVE_COMPARATOR"},{"label":"NCX 470 0.1% (remainder of trial)","type":"EXPERIMENTAL"},{"label":"Latanoprost 0.005% (remainder of trial)","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.","primaryOutcome":{"measure":"Mean IOP Reduction From Time-Matched Baseline at the 8AM and 4PM Time-Points at Week 2, Week 6, and Month 3","timeFrame":"Baseline, Week 2, Week 6, and Month 3","effectByArm":[{"arm":"NCX 470 0.1%","deltaMin":-9.43,"sd":3.443},{"arm":"Latanoprost 0.005%","deltaMin":-8.85,"sd":3.349}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Ocular hyperemia","Conjunctival hyperemia","Instillation site pain","Eye pruritus"]}}